Obstructive sleep apnea affects nearly one billion people worldwide, causing repeated breathing interruptions during sleep. Symptoms include daytime fatigue, headaches and loud snoring, while long-term effects can harm heart health and brain function. Many patients rely on CPAP machines, yet discomfort and inconvenience lead many to abandon treatment. A new oral medication, AD109, has completed a successful phase 3 trial involving 646 participants across the United States and Canada who could not tolerate CPAP. Patients taking the drug nightly for 26 weeks saw their apnea-hypopnea index drop by about 44 percent, compared with 18 percent for those on placebo. Nearly 42 percent moved to a milder category, and 18 percent no longer showed signs of the condition. Side effects were mild and expected. The drug combines aroxybutynin and atomoxetine to maintain upper airway muscle tone during sleep. The US Food and Drug Administration has granted fast-track status, with a decision expected in 2027. Other alternatives, including repurposed medicines and implants, are also under study.
